Issue |
Med Sci (Paris)
Volume 33, Number 3, Mars 2017
Autophagie
|
|
---|---|---|
Page(s) | 328 - 334 | |
Section | M/S Revues | |
DOI | https://doi.org/10.1051/medsci/20173303021 | |
Published online | 03 April 2017 |
L’autophagie : le yin et le yang des cancers
The yin and the yang of autophagy in cancer cells
1
Inserm, UMR1037 CRCT, Centre de recherches en cancérologie de Toulouse, 2, avenue Hubert Curien, CS 53717, F-31037 Toulouse, France
2
Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
3
CNRS, ERL5294 CRCT, F-31000 Toulouse, France
4
Inserm U1218 ACTION, Institut Bergonié, Bordeaux France
5
Université de Bordeaux, Bordeaux France
6
IRCM, Institut de recherche en cancérologie de Montpellier, Montpellier, F-34298, France
7
Inserm, U1194, Montpellier, F-34298, France
8
Université de Montpellier, Montpellier, F-34090, France
9
Institut régional du cancer de Montpellier, Montpellier, F-34298, France
10
European Research Initiative on ALK-related malignancies (ERIA)
L’autophagie est un processus d’autodigestion essentiel au maintien de l’homéostasie cellulaire. Elle se produit à l’état normal mais est également activée en réponse à différents stress. C’est un frein à la formation de tumeurs, mais les cellules cancéreuses peuvent la détourner à leur propre avantage pour favoriser leur développement et/ou résister aux traitements thérapeutiques. Chercheurs et cliniciens sont capables, à l’aide de molécules qui restent à optimiser, de moduler positivement ou négativement ce processus afin d’améliorer l’efficacité des thérapies. L’autophagie est donc au centre d’un véritable « bras de fer » entre les cellules cancéreuses et les thérapies anti-cancéreuses.
Abstract
Autophagy is a self-cannibalism process essential for tissue homeostasis, which can be activated following different environmental stressful conditions. In normal cells, autophagy could act as a brake to prevent tumorigenesis, but cancer cells are able to hijack this process to their own benefit, to promote tumor growth and/or tumor resistance to anti-cancer therapies. Scientists and clinicians attempt to modulate this process to improve therapies, using autophagy inhibitors or activators, some of them being tested currently in clinical trials against several types of tumors. Thus, it appears that autophagy is at the center of a showdown between cancer cells and anti-cancer therapies. In this review, we focus on the mechanisms by which autophagy could be either the yin or the yang of cancers.
© 2017 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.
